AstraZeneca, Pfizer and Moderna appear equivalent in reducing your chance of serious illness from COVID-19.
Academic rigor, journalistic flair
Articles on COVID-19 vaccines
Displaying 241 - 260 of 576 articles
Relying on donor funding means that the funder ultimately determines the health priorities. This is one reason why many programmes in Africa focus on a single disease such as HIV.
At the height of polio and H1N1, Canadians were keen to get vaccinated, but vaccine enthusiasm waned once the crisis had passed — what does that mean for COVID-19?
The pharmaceutical industry overall has been deeply opposed to waiving COVID-19 vaccine patents, but a historian of the industry explains that drug companies once opposed patents altogether.
The federal government has announced COVID-19 vaccination will now become mandatory for aged-care workers. This comes amid a slow and troubled rollout in the sector.
With higher rates of vaccination, the current COVID outbreaks may have been more easily managed.
National policies must incorporate good practices derived from lessons learnt so far to strengthen their health systems. Critical policy elements include preparedness and response.
This myth is still circulating online. Here’s why the chance of this happening is next to zero.
By the time Australia is ready to deliver Novavax, we may well have completed most of the vaccine rollout with AstraZeneca, Pfizer and Moderna. That doesn’t mean Novavax won’t play an important role.
While it’s potentially promising, there’s not enough information yet to determine if the vaccine is safe and effective.
The high costs of the world’s colossally unequal COVID-19 immunization rates.
The vaccine works by the same principles as the Pfizer and Moderna vaccines, and could be manufactured in Australia.
New Zealand’s approval of Pfizer’s COVID-19 vaccine for 12-15 year olds will bring the number of people eligible for the jab to 85% of the population, raising the chance of reaching collective immunity.
China has administered more than one billion doses of its homegrown COVID-19 vaccines, the majority of which were developed by local companies Sinovac and Sinopharm. So what do we know about them?
In Australia, a preference for a particular brand of COVID vaccine is likely to change, depending on the latest health advice, and media reports.
Psychologists have identified three potential barriers to vaccination: capability, opportunity and motivation.
Our brains cannot easily understand tiny risks so we tend to overestimate them. That’s when we need a little extra help to make the best decisions about our health.
It’s OK to wait longer than three weeks between Pfizer doses, and this may even provide stronger protection. But this must be weighed against the risk of contracting COVID in the meantime.
Various companies use different ingredients and different delivery systems in their COVID-19 vaccines. Researchers are investigating whether it’s better for individuals to mix what’s available.
Even if we came up with a definition of what makes the “best” vaccine, we don’t have the luxury of choice, when vaccines are in short supply.
Top contributors
-
Associate professor, UNSW Sydney
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Associate Professor, School of Social Sciences, The University of Western Australia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor, Epidemiology, Deakin University
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Assistant Professor of Political Science, Oklahoma State University
-
Instructor of Human Immunology, Emory University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Chair in Epidemiology, Deakin University
